[go: up one dir, main page]

MX2019015769A - Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno. - Google Patents

Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno.

Info

Publication number
MX2019015769A
MX2019015769A MX2019015769A MX2019015769A MX2019015769A MX 2019015769 A MX2019015769 A MX 2019015769A MX 2019015769 A MX2019015769 A MX 2019015769A MX 2019015769 A MX2019015769 A MX 2019015769A MX 2019015769 A MX2019015769 A MX 2019015769A
Authority
MX
Mexico
Prior art keywords
redirectors
antigen
particles
specific
immune responses
Prior art date
Application number
MX2019015769A
Other languages
English (en)
Inventor
Joshua Weiyuan Wang
Nattha Ingavat
Original Assignee
Verimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verimmune Inc filed Critical Verimmune Inc
Publication of MX2019015769A publication Critical patent/MX2019015769A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16723—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a partículas tipo virus (VLP) quiméricas ensambladas a partir de un polipéptido que comprende una proteína L1 o proteína L1/L2 del virus del papiloma (VP) y un péptido diana que comprende un epítopo de linfocitos T CD8+ derivado de un patógeno humano. La presente invención también se refiere a métodos que 5 usan las VLP quiméricas como redireccionadores de respuestas inmunitarias específicos para el antígeno.
MX2019015769A 2017-06-23 2018-06-21 Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno. MX2019015769A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524308P 2017-06-23 2017-06-23
US201862676566P 2018-05-25 2018-05-25
PCT/US2018/038701 WO2018237115A2 (en) 2017-06-23 2018-06-21 Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses

Publications (1)

Publication Number Publication Date
MX2019015769A true MX2019015769A (es) 2020-08-03

Family

ID=64737338

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015769A MX2019015769A (es) 2017-06-23 2018-06-21 Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno.

Country Status (13)

Country Link
US (3) US11285203B2 (es)
EP (1) EP3641809A4 (es)
JP (1) JP2020524710A (es)
KR (1) KR102797824B1 (es)
CN (1) CN110891602A (es)
AU (1) AU2018289540B2 (es)
BR (1) BR112019027488A2 (es)
CA (1) CA3068012A1 (es)
IL (1) IL271461B2 (es)
MX (1) MX2019015769A (es)
MY (1) MY202196A (es)
SG (1) SG11201912480SA (es)
WO (1) WO2018237115A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813329B2 (en) * 2014-10-24 2023-11-14 Hpvvax, Llc Method and composition for treating cancer or skin lesion using a vaccine
MX2019015769A (es) * 2017-06-23 2020-08-03 Verimmune Inc Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno.
US11560408B2 (en) 2018-12-27 2023-01-24 Verimmune Inc. Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
CN114805598A (zh) * 2019-04-28 2022-07-29 广州市雷德生物科技有限公司 促进蛋白二聚体形成的拉链扣结构及其应用
AU2021364548A1 (en) * 2020-10-19 2023-06-08 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
CN115960262A (zh) * 2022-10-19 2023-04-14 四川农业大学 展示cdv抗原表位的犬细小病毒样颗粒及构建方法和应用
WO2024254149A2 (en) * 2023-06-06 2024-12-12 Verlmmune Inc. Virus-inspired compositions comprising virus-like proteins and checkpoint inhibitors, and methods of use thereof to treat cancer

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020039584A1 (en) * 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
SK7602001A3 (en) 1998-12-04 2002-03-05 Biogen Inc Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
SE514982C2 (sv) 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
NZ542226A (en) 2003-03-07 2008-08-29 Merck & Co Inc Influenza virus vaccine
CN100385011C (zh) 2003-05-09 2008-04-30 研究发展基金会 在膜蛋白中插入弗林蛋白酶切割位点及其用途
KR20080015854A (ko) * 2005-06-14 2008-02-20 사이토스 바이오테크놀로지 아게 항원 컨쥬게이트 및 그의 용도
US20070160628A1 (en) 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2632663C (en) 2005-12-08 2015-08-18 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
US8778351B2 (en) * 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
SI2145189T1 (sl) 2007-05-08 2016-08-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papilomavirusni psevdovirusi za detekcijo in terapijo tumorjev
US8088392B2 (en) 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
EP2217699A4 (en) * 2007-10-22 2012-11-28 Univ Rochester VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS BASED ON CAPSOMERS OR CHIMERIC PARTICLES SIMILAR TO PAPILLOMAVIRUS VIRUS
WO2009092113A2 (en) 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
RU2509570C2 (ru) 2008-06-09 2014-03-20 Бхарат Байотек Интернэшнл Лимитед Вакцинная композиция, пригодная при инфекциях hpv и вирусом гепатита в, и способ ее получения
DK2416798T3 (en) 2009-04-10 2018-01-08 Univ Johns Hopkins PAPILLOMAVIRUS-LIKE PARTICLES (VLP) AS WIDE-SPECIFIED VACCINES AGAINST HUMAN PAPILLOMAVIRUS (HPV)
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
CN102413838A (zh) 2009-04-30 2012-04-11 科勒制药集团有限公司 肺炎球菌疫苗及其用途
US9580474B2 (en) * 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
CN102153656B (zh) * 2011-01-12 2014-11-19 广州市元通医药科技有限公司 一种嵌合病毒样颗粒疫苗及其制备方法
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
JP6228922B2 (ja) 2011-12-01 2017-11-08 ユニバーシティ・オブ・ケープ・タウンＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｐｅ Ｔｏｗｎ Ｈｐｖキメラ粒子
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
WO2014043523A1 (en) 2012-09-14 2014-03-20 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing
WO2014145932A2 (en) 2013-03-15 2014-09-18 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
ES2729841T3 (es) 2013-09-18 2019-11-06 Aura Biosciences Inc Conjugados de partículas similares a virus para tratar tumores
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
US10413603B2 (en) 2014-06-19 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for improved human papilloma virus constructs
EP3244915A1 (en) * 2015-01-15 2017-11-22 University of Copenhagen Virus-like particle with efficient epitope display
KR20170116039A (ko) 2015-02-18 2017-10-18 에프. 호프만-라 로슈 아게 표적 세포에 대항하여 t 세포 세포독성을 특이적으로 유도하기 위한 면역컨주게이트
CN115068597A (zh) 2015-04-28 2022-09-20 阿尔伯特爱因斯坦医学院 使用由减毒细菌递送的回忆抗原治疗癌症
WO2017020570A1 (en) 2015-08-06 2017-02-09 Medigen Biotechnology Corp. Virus-like particle vaccines
WO2017075615A1 (en) * 2015-10-29 2017-05-04 Bullet Biotechnology, Inc. Virus-like particle intermediates, agents attached thereto, methods for making and uses thereof
KR20180095511A (ko) 2015-10-30 2018-08-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 표적화된 암 요법
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
US20180311374A1 (en) 2015-10-30 2018-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Targeted cancer therapy
US10722537B2 (en) 2015-11-06 2020-07-28 Regents Of The University Of Minnesota Activation of resident memory T cells for cancer immunotherapy
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
EP3393511A1 (en) 2015-12-21 2018-10-31 La Jolla Institute for Allergy and Immunology Leveraging immune memory from common childhood vaccines to fight disease
US11351237B2 (en) 2015-12-22 2022-06-07 Thomas Jefferson University CMV-based intra-tumoral cancer therapies
GB201603625D0 (en) * 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
WO2017177204A1 (en) 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
US20200078401A1 (en) 2016-12-07 2020-03-12 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US11197890B2 (en) 2016-12-12 2021-12-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
MX2019015769A (es) * 2017-06-23 2020-08-03 Verimmune Inc Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno.
EP3661550A4 (en) 2017-08-03 2021-08-04 Regents of the University of Minnesota ACTIVATION OF LYMPHOCYTES T MEMORY RESIDENTS FOR THE TREATMENT OF CANCER
CN120392995A (zh) 2017-11-06 2025-08-01 美利坚合众国,由健康及人类服务部部长代表 利用预先存在的微生物免疫的癌症治疗
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
DE102018123327A1 (de) * 2018-09-21 2020-03-26 Christian Uhlik Modulares Raumluft-Behandlungssystem
US11560408B2 (en) * 2018-12-27 2023-01-24 Verimmune Inc. Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
KR20210151848A (ko) 2019-03-26 2021-12-14 아우라 바이오사시언시스, 인크. 인간 파필로마바이러스 나노입자 제제
AU2021364548A1 (en) * 2020-10-19 2023-06-08 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Also Published As

Publication number Publication date
CA3068012A1 (en) 2018-12-27
AU2018289540B2 (en) 2024-06-13
US11944677B2 (en) 2024-04-02
AU2018289540A1 (en) 2020-01-16
US20200113996A1 (en) 2020-04-16
US20220226460A1 (en) 2022-07-21
MY202196A (en) 2024-04-16
SG11201912480SA (en) 2020-01-30
US20240390473A1 (en) 2024-11-28
EP3641809A2 (en) 2020-04-29
CN110891602A (zh) 2020-03-17
IL271461B2 (en) 2023-09-01
IL271461A (en) 2020-01-30
IL271461B1 (en) 2023-05-01
KR102797824B1 (ko) 2025-04-17
JP2020524710A (ja) 2020-08-20
WO2018237115A3 (en) 2019-01-31
KR20200027956A (ko) 2020-03-13
BR112019027488A2 (pt) 2020-07-07
US11285203B2 (en) 2022-03-29
EP3641809A4 (en) 2021-04-21
WO2018237115A2 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
MY202196A (en) Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
PH12017500727A1 (en) Modified virus-like particles of cmv
MX2025009589A (es) Vacunas a base de peptidos, metodos de fabricacion y sus usos para inducir una respuesta inmune
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX387666B (es) Composiciones y su uso en el tratamiento de citomegalovirus
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
AU2015204503A8 (en) Novel vaccines against HPV and HPV-related diseases
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
MX2017008187A (es) Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
AU2016219317A8 (en) Methods and compositions useful in generating non canonical CD8+ T cell responses
SG11202106931PA (en) Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
EA201790680A1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) для популяции антигенов
WO2016116905A9 (en) Cmv antigens and uses thereof
MA40624A (fr) Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
NZ760789A (en) Uti fusion proteins
WO2019209859A8 (en) Chimeric vectors
WO2015149016A3 (en) Breast and ovarian cancer vaccines
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
WO2015086354A3 (en) Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
EP3804748A4 (en) Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof